<!DOCTYPE html><html><head><title>Chronic obstructive pulmonary disease.</title><link rel="stylesheet" type="text/css" href="style.css"></head><body><div class='section'>
<h2>General
</h2>
<div class='field field_text'>
<h3>
Guideline Title
</h3>
<div class='FieldValue'>
<div class="content_title">Chronic obstructive pulmonary disease.</div>
</div>

</div>
<div class='field field_citation'>
<h3>
Bibliographic Source(s)
</h3>
<div class='FieldValue'>
<table><tr><td>University of Michigan Health System. Chronic obstructive pulmonary disease. Ann Arbor (MI): University of Michigan Health System; 2017 Nov. 28 p.  [99 references]</td></tr></table>
</div>

</div>
<div class='field field_text'>
<h3>
Guideline Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This is the current release of the guideline.</p>
<p>This guideline updates a previous version: University of Michigan Health System. Chronic obstructive pulmonary disease. Ann Arbor (MI): University of Michigan Health System; 2010 May. 17 p. [7 references]</p>
<p>This guideline meets NGC's 2013 (revised) inclusion criteria.</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>NEATS Assessment
</h2>
<div class='field field_picklist-one'>
<h3>
Disclosure of Guideline Funding Source
</h3>
<div class='FieldValue'>
Yes
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Disclosure and Management of Financial Conflict of Interests
</h3>
<div class='FieldValue'>
4
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Guideline Development Group Composition: Multidisciplinary Group
</h3>
<div class='FieldValue'>
Yes
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Guideline Development Group Composition: Methodologist Involvement
</h3>
<div class='FieldValue'>
Yes
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Guideline Development Group Composition: Patient and Public Perspectives
</h3>
<div class='FieldValue'>
1
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Use of a Systematic Review of Evidence: Search Strategy
</h3>
<div class='FieldValue'>
5
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Use of a Systematic Review of Evidence: Study Selection
</h3>
<div class='FieldValue'>
5
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Use of a Systematic Review of Evidence: Synthesis of Evidence
</h3>
<div class='FieldValue'>
4
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Evidence Foundations for and Rating Strength of Recommendations: Grading the Quality or Strength of Evidence
</h3>
<div class='FieldValue'>
3
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Evidence Foundations for and Rating Strength of Recommendations: Benefits and Harms of Recommendations
</h3>
<div class='FieldValue'>
4
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Evidence Foundations for and Rating Strength of Recommendations: Evidence Summary Supporting Recommendations
</h3>
<div class='FieldValue'>
3
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Evidence Foundations for and Rating Strength of Recommendations: Rating the Strength of Recommendations
</h3>
<div class='FieldValue'>
2
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Specific and Unambiguous Articulation of Recommendations
</h3>
<div class='FieldValue'>
3
</div>

</div>
<div class='field field_picklist-one'>
<h3>
External Review
</h3>
<div class='FieldValue'>
1
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Updating
</h3>
<div class='FieldValue'>
5
</div>

</div>

</div>
<div class='section'>
<h2>Recommendations
</h2>
<div class='field field_text'>
<h3>
Major Recommendations
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong><em>Note from the University of Michigan Health System (UMHS) and the National Guideline Clearinghouse (NGC)</em></strong>: The following guidance was current as of November 2017. Because UMHS occasionally releases minor revisions to its guidance based on new information, users may wish to consult the <a href="http://www.med.umich.edu/1info/FHP/practiceguides/copd/copd.pdf" title="UMHS Web site">original guideline document</a> for the most current version.</p>
<p><strong>Note from NGC</strong>: The following key points summarize the content of the guideline. Refer to the original guideline document for additional information.</p>
<p>The strength of recommendation (I-III) and levels of evidence (A-E) are defined at the end of the "Major Recommendations" field.</p>
<p><strong><span style="text-decoration: underline;">Key Points</span></strong></p>
<p>Chronic obstructive pulmonary disease (COPD) is underdiagnosed and misdiagnosed. See Table 1 in the original guideline document for an overview of diagnosis and management of COPD.</p>
<p>Do not perform population-wide screening for COPD <em>[III-C]</em>.</p>
<p>Appropriate comprehensive treatment can improve symptoms and quality of life <em>[I-A]</em>.</p>
<p><strong><span style="text-decoration: underline;">Diagnosis</span></strong></p>
<p>Consider COPD in any patient with dyspnea, chronic cough or sputum production <em>[I-C]</em>. Consider early diagnostic case finding in persons with a history of inhalation exposures known to be risk factors for COPD <em>[I-D]</em>. </p>
<p>Pulmonary function testing with post-bronchodilator assessment demonstrating a reduced forced expiratory volume in the first second/forced vital capacity (FEV<sub>1</sub>/FVC) ratio is required for diagnosis <em>[I-C]</em>.</p>
<p>Assess COPD severity by determining extent of airflow limitation (spirometry), symptom severity, and exacerbation history (see Table 5 in the original guideline document) <em>[I-C]</em>.</p>
<p><strong><span style="text-decoration: underline;">Treatment</span></strong></p>
<p>Smoking cessation is the single most important intervention to slow the rate of lung function decline, regardless of disease severity <em>[I-C]</em>.</p>
<p>Chronic medication management includes:</p>
<ul style="list-style-type: disc;">
    <li>Bronchodilators (beta-2 agonists and anticholinergics), selected based on symptoms and severity (see Figure 1 &amp; Table 7 in the original guideline document), with the goal of improving symptoms and functioning and reducing exacerbations <em>[I-A]</em>. </li>
    <li>Inhaled corticosteroids &ndash; consider adding to bronchodilators for patients with frequent exacerbations despite bronchodilator therapy <em>[I-A]</em> or with features suggestive of asthma-COPD overlap <em>[II-D]</em>. </li>
    <li>Supplemental oxygen if resting oxygen saturation &le;88% or arterial partial pressure of oxygen (PaO<sub>2</sub>) &le; 55 mm Hg <em>[I-A]</em>. </li>
</ul>
<p>Acute exacerbation medication management includes bronchodilators (beta-2 agonists and anticholinergics) <em>[I-C]</em>, systemic corticosteroid therapy <em>[I-A]</em>, and antibiotics <em>[II-A]</em> based on clinical indications (see Table 9 in the original guideline document). Empiric antibiotics are recommended for patients with increased sputum purulence plus either increased dyspnea or increased sputum volume <em>[I-A]</em>. Sputum culture is not routinely recommended <em>[III-D]</em>.</p>
<p>Pulmonary rehabilitation should be considered for all patients with functional impairment <em>[I-A]</em>.</p>
<p>Surgical and minimally invasive options include bullectomy, lung volume reduction procedures, and lung transplantation <em>[II-B]</em>. Life expectancy should be incorporated into shared decision making regarding the potential benefits of surgery <em>[II-D]</em>. Pulmonary consultation is recommended prior to consideration of invasive options <em>[I-D]</em>.</p>
<p>Palliative care should be discussed with patients with advanced COPD. Doing so may help limit unnecessary and burdensome personal and societal costs and invasive approaches <em>[I-C]</em>.</p>
<p><strong><span style="text-decoration: underline;">Definitions</span></strong></p>
<p><strong>Levels of Evidence</strong></p>
<ol style="list-style-type: upper-alpha;" start="1">
    <li>Systematic reviews of randomized controlled trials </li>
    <li>Randomized controlled trials </li>
    <li>Systematic review of non-randomized controlled trials or observational studies, non-randomized controlled trials, group observation studies (e.g., cohort, cross-sectional, case-control) </li>
    <li>Individual observation studies (case study or case series) </li>
    <li>Opinion of expert panel </li>
</ol>
<p><strong>Strength of Recommendation</strong></p>
<ol style="list-style-type: upper-roman;">
    <li>Generally should be performed </li>
    <li>May be reasonable to perform </li>
    <li>Generally should not be performed </li>
</ol></div>
</div>

</div>
<div class='field field_text'>
<h3>
Clinical Algorithm(s)
</h3>
<div class='FieldValue'>
<div class="content_para"><p>An algorithm titled "Overview of COPD Management: Patient Education, Preventive Care, Pharmacologic Therapy, and Pulmonary Rehabilitation" is provided in the original guideline document.</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Scope
</h2>
<div class='field field_text'>
<h3>
Disease/Condition(s)
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Chronic obstructive pulmonary disease (COPD)</p></div>
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Guideline Category
</h3>
<div class='FieldValue'>
Diagnosis
</div>
<div class='FieldValue'>
Evaluation
</div>
<div class='FieldValue'>
Management
</div>
<div class='FieldValue'>
Prevention
</div>
<div class='FieldValue'>
Treatment
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Clinical Specialty
</h3>
<div class='FieldValue'>
Critical Care
</div>
<div class='FieldValue'>
Family Practice
</div>
<div class='FieldValue'>
Internal Medicine
</div>
<div class='FieldValue'>
Preventive Medicine
</div>
<div class='FieldValue'>
Pulmonary Medicine
</div>
<div class='FieldValue'>
Thoracic Surgery
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Intended Users
</h3>
<div class='FieldValue'>
Advanced Practice Nurses
</div>
<div class='FieldValue'>
Nurses
</div>
<div class='FieldValue'>
Occupational Therapists
</div>
<div class='FieldValue'>
Pharmacists
</div>
<div class='FieldValue'>
Physician Assistants
</div>
<div class='FieldValue'>
Physicians
</div>
<div class='FieldValue'>
Respiratory Care Practitioners
</div>

</div>
<div class='field field_text'>
<h3>
Guideline Objective(s)
</h3>
<div class='FieldValue'>
<ul style="list-style-type: disc;">
    <li>To provide a framework for management of chronic obstructive pulmonary disease (COPD) and for the treatment of mild to moderate acute exacerbations</li>
    <li>To improve symptoms, quality of life and lung function while reducing morbidity and mortality for patients with COPD </li>
</ul>
</div>

</div>
<div class='field field_text'>
<h3>
Target Population
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Adults with chronic obstructive pulmonary disease (COPD)</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Interventions and Practices Considered
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong><span style="text-decoration: underline;">Diagnosis</span></strong></p>
<ol style="list-style-type: decimal;">
    <li>Consideration of a diagnosis of chronic obstructive pulmonary disease (COPD) in patients with dyspnea, chronic cough, sputum production, or a history of inhalation exposures </li>
    <li>Pulmonary function testing with post-bronchodilator assessment </li>
    <li>Assessment of COPD severity </li>
</ol>
<p><strong><span style="text-decoration: underline;">Treatment</span></strong></p>
<ol style="list-style-type: decimal;">
    <li>Smoking cessation </li>
    <li>Chronic and acute medication management
    <ul>
        <li>Bronchodilators (beta-2-agonists and anticholinergics) </li>
        <li>Inhaled corticosteroids </li>
        <li>Systemic corticosteroids </li>
        <li>Supplemental oxygen </li>
        <li>Antibiotics </li>
    </ul>
    </li>
    <li>Pulmonary rehabilitation </li>
    <li>Bullectomy </li>
    <li>Lung volume reduction surgery </li>
    <li>Lung transplantation </li>
    <li>Palliative care </li>
</ol></div>
</div>

</div>
<div class='field field_text'>
<h3>
Major Outcomes Considered
</h3>
<div class='FieldValue'>
<ul style="list-style-type: disc;">
    <li>Predictive sensitivity/specificity of diagnostic tests </li>
    <li>Disease severity </li>
    <li>Disease progression </li>
    <li>Morbidity </li>
    <li>Mortality </li>
    <li>Quality of life </li>
    <li>Cost of treatment </li>
    <li>Adverse events of medication</li>
    <li>Pulmonary function </li>
</ul>
</div>

</div>

</div>
<div class='section'>
<h2>Methodology
</h2>
<div class='field field_picklist-many'>
<h3>
Methods Used to Collect/Select the Evidence
</h3>
<div class='FieldValue'>
Hand-searches of Published Literature (Primary Sources)
</div>
<div class='FieldValue'>
Hand-searches of Published Literature (Secondary Sources)
</div>
<div class='FieldValue'>
Searches of Electronic Databases
</div>

</div>
<div class='field field_text'>
<h3>
Description of Methods Used to Collect/Select the Evidence
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong><span style="text-decoration: underline;">Literature Search</span></strong></p>
<p>The team began the search of literature by accepting the results of a systematic literature review performed in 2014:</p>
<ul style="list-style-type: disc;">
    <li>VA/DoD Clinical Practice Guideline for the Management of Chronic Obstructive Pulmonary Disease. The Management of Chronic Obstructive Pulmonary Disease Working Group, Department of Veterans Affairs and Department of Defense. Dec. 2014. (Searched literature from January 2005 through February 2014.) (See the "Availability of Companion Documents" field) </li>
</ul>
<p>To update those results, they performed a systematic search of literature on Medline and in the Cochrane Database of Systematic Reviews for the time period 1/1/14&ndash;9/8/16.</p>
<p>The major search term was chronic obstructive pulmonary disease. The searches were for guidelines, controlled trials (including meta-analyses), and cohort studies, for literature on humans in the English language. Within these parameters individual searches were performed for the following topics:</p>
<ol style="list-style-type: upper-alpha;">
    <li>Etiology: smoking, particulate inhalation exposures, alpha-1 antitrypsin deficiency, life expectancy based on forced expiratory volume in the first second (FEV<sub>1</sub>)/Body-mass index, airflow Obstruction, Dyspnea, and Exercise (BODE) </li>
    <li>Screening: questionnaires, pulmonary function testing/spirometry </li>
    <li>Diagnosis: History (risk factors, symptoms), physical exam </li>
    <li>Diagnostic studies: pulmonary function tests (PFTs), alpha-1 antitrypsin level, chest X-ray, 6-minute walk test, chest computed tomography (CT) </li>
    <li>Diagnostic classification: Global Initiative for Chronic Obstructive Lung Disease (GOLD) classes, Medical Research Council (MRC) or Modified Medical Research Council (mMRC) dyspnea scale, BODE index </li>
    <li>Definition and diagnosis: acute exacerbation </li>
    <li>Other diagnoses not included in C&ndash;F above </li>
    <li>Comorbid diseases (increased risk) </li>
    <li>Prevention: smoking cessation, vaccination (influenza, pneumococcus) </li>
    <li>Prevention: irritant avoidance </li>
    <li>Pharmacologic treatment: bronchodilators, inhaled corticosteroids </li>
    <li>Treatment: supplemental oxygen </li>
    <li>Treatment: pulmonary rehabilitation </li>
    <li>Nutrition </li>
    <li>Treatment: complementary and alternative medicine </li>
    <li>Treatment: mental health, psychosocial support </li>
    <li>Treatment: acute exacerbation &ndash; outpatient management, hospitalization </li>
    <li>Referral to pulmonary subspecialist </li>
    <li>Surgical treatment: lung volume reduction surgery, lung transplantation </li>
    <li>Treatment: follow up care, monitoring, chronic disease management </li>
    <li>Treatment: palliative care </li>
    <li>Other "treatments" not in I&ndash;U above </li>
    <li>Other not in A&ndash;V above </li>
</ol>
<p>The search was conducted in components of a formal problem structure (outlined above). The search was supplemented with very recent clinical trials known to expert members of the panel. The search was a single cycle.</p>
<p>A more formal presentation of the inclusion and exclusion criteria, as well as the detailed search strategies, are presented in the methodological appendix (see the "Availability of Companion Documents" field).</p>
<p><strong><span style="text-decoration: underline;">Literature Review and Assessment</span></strong></p>
<p>Members of the guideline team reviewed the publications identified to be relevant to specific topics in order to select those with best evidence. Criteria to identify overall best evidence included relevance of the study setting and population, study design, sample size, measurement methods (variables, measures, data collection), intervention methods (appropriateness, execution), appropriateness of analyses, and clarity of description.</p>
<p>Beginning with best evidence identified by the VA/DoD systematic literature review, team members checked publications identified in the more recent search (1/1/14&ndash;9/8/16) to determine whether better evidence was available. Team members also had the option of considering very recent literature (published since 9/8/16) in determining whether even better evidence was available.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Number of Source Documents
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The review process resulted in 56 studies identified as presenting best evidence on a topic by either the VA/DoD literature review or the review of more recent evidence.</p>
<p>The number of publications identified is presented in Section IV of the accompanying Literature Review Methods and Results (see the "Availability of Companion Documents" field).</p></div>
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Methods Used to Assess the Quality and Strength of the Evidence
</h3>
<div class='FieldValue'>
Weighting According to a Rating Scheme (Scheme Given)
</div>

</div>
<div class='field field_text'>
<h3>
Rating Scheme for the Strength of the Evidence
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong><span style="text-decoration: underline;">Levels of Evidence</span></strong></p>
<ol style="list-style-type: upper-alpha;">
    <li>Systematic reviews of randomized controlled trials </li>
    <li>Randomized controlled trials </li>
    <li>Systematic review of non-randomized controlled trials or observational studies, non-randomized controlled trials, group observation studies (e.g., cohort, cross-sectional, case-control) </li>
    <li>Individual observation studies (case study or case series) </li>
    <li>Opinion of expert panel </li>
</ol></div>
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Methods Used to Analyze the Evidence
</h3>
<div class='FieldValue'>
Review of Published Meta-Analyses
</div>
<div class='FieldValue'>
Systematic Review with Evidence Tables
</div>

</div>
<div class='field field_text'>
<h3>
Description of the Methods Used to Analyze the Evidence
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The best evidence regarding specific topics was summarized in evidence tables listing articles, study designs, patient populations, main outcome variables, results, and notes regarding methodological issues and harms.</p>
<p>The process of review and assessment is described in more detail in the methods companion (see the "Availability of Companion Documents" field). </p></div>
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Methods Used to Formulate the Recommendations
</h3>
<div class='FieldValue'>
Expert Consensus
</div>

</div>
<div class='field field_text'>
<h3>
Description of Methods Used to Formulate the Recommendations
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The guideline team reviewed the evidence and determined the importance of performing or not performing key aspects of care. In the absence of empirical evidence, the guideline team based recommendations on their expert opinion.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Rating Scheme for the Strength of the Recommendations
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong><span style="text-decoration: underline;">Strength of Recommendation</span></strong></p>
<ol style="list-style-type: upper-roman;">
    <li>Generally should be performed </li>
    <li>May be reasonable to perform </li>
    <li>Generally should not be performed </li>
</ol></div>
</div>

</div>
<div class='field field_text'>
<h3>
Cost Analysis
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Cost-effectiveness of lung volume reduction surgery is not demonstrated for even the most favorable subgroup (i.e., chronic obstructive pulmonary disease [COPD] patients with upper lobe emphysema and reduced exercise capacity) unless outcomes are expected to remain favorable for 10 years.</p></div>
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Method of Guideline Validation
</h3>
<div class='FieldValue'>
Internal Peer Review
</div>

</div>
<div class='field field_text'>
<h3>
Description of Method of Guideline Validation
</h3>
<div class='FieldValue'>
<div class="content_para"><p>A draft of this guideline was reviewed in clinical conferences and by distribution for comment within departments and divisions of University of Michigan Health System (UMHS) to which the content is most relevant: Emergency Medicine, Family Medicine, General Medicine, Geriatric Medicine, Obstetrics &amp; Gynecology (Women's Health), and Pulmonary &amp; Critical Care Medicine. The draft was revised based on comments from these groups.</p>
<p>The final version of this guideline was endorsed by the Clinical Practice Committee of the University of Michigan Medical Group and by the Executive Committee for Clinical Affairs of the University of Michigan Hospitals and Health Centers.</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Evidence Supporting the Recommendations
</h2>
<div class='field field_text'>
<h3>
Type of Evidence Supporting the Recommendations
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The type of supporting evidence is identified and graded for each recommendation (see the "Major Recommendations" field).</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Benefits/Harms of Implementing the Guideline Recommendations
</h2>
<div class='field field_text'>
<h3>
Potential Benefits
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Chronic obstructive pulmonary disease (COPD) is responsive to multiple treatments. Appropriate comprehensive treatment can improve patients' quality of life and prognosis.</p>
<p>Refer to the "Clinical Background and Rationale for Recommendations" section of the original guideline document for the benefits of specific interventions. </p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Potential Harms
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong><span style="text-decoration: underline;">Long-Acting Beta-2-Agonists (LABAs) and Anticholinergics</span></strong></p>
<ul style="list-style-type: disc;">
    <li><em>LABAs</em>. A U.S. Food and Drug Administration (FDA) advisory panel recommended that LABAs not be used as single-agent therapy in asthma (see <a href="http://www.med.umich.edu/1info/FHP/practiceguides/asthma.html" title="University of Michigan Health System (UMHS) Web site">University of Michigan Health System [UMHS] Asthma guideline</a>). However, for patients with chronic obstructive pulmonary disease (COPD), LABAs may still be used as single-agent therapy without an inhaled corticosteroid. While LABAs may increase blood pressure and heart rate, data for COPD patients from the TORCH study (a three-year trial in COPD patients of fluticasone propionate and salmeterol combination versus fluticasone alone, salmeterol alone, or placebo), found no increased risk of all-cause death or cardiovascular death in the salmeterol group. These data further underscore the importance of distinguishing asthma from COPD. </li>
    <li><em>Anticholinergics</em>. Anticholinergic drugs may worsen symptoms and signs associated with narrow-angle glaucoma, prostatic hyperplasia, or bladder-neck obstruction and should be used with caution in patients with any of these conditions. Concerns about cardiovascular effects have diminished. Initially a meta-analysis suggested that inhaled anticholinergics (ipratropium and tiotropium) were associated with significantly increased risk of cardiovascular death, myocardial infarction (MI), or stroke among patients with COPD. However, since then, data from the UPLIFT study (a four-year, placebo controlled trial of tiotropium) found no significant increase in MI or stroke in the tiotropium treated group. </li>
</ul>
<p><strong><span style="text-decoration: underline;">Inhaled Glucocorticosteroids (ICS)</span></strong></p>
<ul style="list-style-type: disc;">
    <li>Withdrawal from treatment with ICS can lead to a short term increase in exacerbations in some patients. </li>
    <li>An increase in the frequency of pneumonia has been reported in COPD patients using ICS, particularly in patients age 65 and older. The frequency of reported pneumonia appears to be approximately double in several studies comparing ICS/LABA combinations versus placebo in COPD. However, in the largest published mortality study in COPD, no increase in pulmonary related deaths was noted in the ICS/LABA combination therapy group as compared to placebo. In patients with COPD being treated with ICS, particularly those age 65 and older, consider the possible increased risk of pneumonia and maintain a lower threshold for considering a diagnosis of pneumonia when patients present with increased symptoms. </li>
    <li>ICS may also increase a patient's risk for cataracts or glaucoma. Consider regular eye exams for patients using these medications. Patients using ICS should also be warned about the possibility of oral candidiasis and vocal changes. Rinsing the mouth after administration of ICS should be encouraged. </li>
    <li>Decrease in bone density is a theoretical risk of this class of medication, but available long-term data suggest there is no meaningful association between ICS use and decreased bone mineral density in this patient population. </li>
</ul></div>
</div>

</div>

</div>
<div class='section'>
<h2>Qualifying Statements
</h2>
<div class='field field_text'>
<h3>
Qualifying Statements
</h3>
<div class='FieldValue'>
<div class="content_para"><p>These guidelines should not be construed as including all proper methods of care or excluding other acceptable methods of care reasonably directed to obtaining the same results. The ultimate judgment regarding any specific clinical procedure or treatment must be made by the physician in light of the circumstances presented by the patient.</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Implementation of the Guideline
</h2>
<div class='field field_text'>
<h3>
Description of Implementation Strategy
</h3>
<div class='FieldValue'>
<div class="content_para"><p>An implementation strategy was not provided.</p></div>
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Implementation Tools
</h3>
<div class='FieldValue'>
Audit Criteria/Indicators
</div>
<div class='FieldValue'>
Clinical Algorithm
</div>
<div class='FieldValue'>
Patient Resources
</div>
<div class='FieldValue'>
Staff Training/Competency Material
</div>

</div>

</div>
<div class='section'>
<h2>Institute of Medicine (IOM) National Healthcare Quality Report Categories
</h2>
<div class='field field_picklist-many'>
<h3>
IOM Care Need
</h3>
<div class='FieldValue'>
End of Life Care
</div>
<div class='FieldValue'>
Getting Better
</div>
<div class='FieldValue'>
Living with Illness
</div>

</div>
<div class='field field_picklist-many'>
<h3>
IOM Domain
</h3>
<div class='FieldValue'>
Effectiveness
</div>
<div class='FieldValue'>
Patient-centeredness
</div>

</div>

</div>
<div class='section'>
<h2>Identifying Information and Availability
</h2>
<div class='field field_citation'>
<h3>
Bibliographic Source(s)
</h3>
<div class='FieldValue'>
<table><tr><td>University of Michigan Health System. Chronic obstructive pulmonary disease. Ann Arbor (MI): University of Michigan Health System; 2017 Nov. 28 p.  [99 references]</td></tr></table>
</div>

</div>
<div class='field field_text'>
<h3>
Adaptation
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Not applicable: The guideline was not adapted from another source.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Date Released
</h3>
<div class='FieldValue'>
2017 Nov
</div>

</div>
<div class='field field_orglist-p'>
<h3>
Guideline Developer(s)
</h3>
<div class='FieldValue'>
University of Michigan Health System - Academic Institution
</div>

</div>
<div class='field field_text'>
<h3>
Source(s) of Funding
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The development of this guideline was funded by University of Michigan Health System (UMHS).</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Guideline Committee
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Chronic Obstructive Pulmonary Disease (COPD) Guideline Team</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Composition of Group That Authored the Guideline
</h3>
<div class='FieldValue'>
<div class="content_para"><p><em>Team Leader</em>: Davoren A Chick, MD, General Medicine</p>
<p><em>Team Members</em>: Paul J Grant, MD, General Medicine; R Van Harrison, PhD, Learning Health Sciences; Amal Othman, MD, Family Medicine; Sarah E Roark, MD, Pulmonary Medicine; Meilan K Han, MD, MS, Pulmonary Medicine</p>
<p><em>Consultant</em>: Tami L Remington, PharmD, Pharmacy Services</p>
<p><em>Ambulatory Clinical Guidelines Oversight</em>: Karl T Rew, MD; R Van Harrison, PhD</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Financial Disclosures/Conflicts of Interest
</h3>
<div class='FieldValue'>
<div class="content_para"><p>University of Michigan Health System (UMHS) endorses the Standards of the Accreditation Council for Continuing Medical Education that the individuals who present educational activities disclose significant relationships with commercial companies whose products or services are discussed. Contributions of team members with relevant financial relationships are reviewed by team members without relevant financial relationships to assure the information is presented without bias.</p>
<p><span style="text-decoration: underline;">Individuals with no relevant personal financial relationships</span>: Davoren A Chick, MD; Paul J Grant, MD; R Van Harrison, PhD; Amal E Othman, MD; Tami L Remington, PharmD; and Sarah E Roark, MD</p>
<p><span style="text-decoration: underline;">Individuals with relevant personal financial relationships</span>: MeiLan K Han, MD, consultant for Novartis, Nycomed; speaker's bureau for Boehringer Ingelheim, GlaxoSmithKline, and CLS Boehring; advisory board for CLS Boehring</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Guideline Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This is the current release of the guideline.</p>
<p>This guideline updates a previous version: University of Michigan Health System. Chronic obstructive pulmonary disease. Ann Arbor (MI): University of Michigan Health System; 2010 May. 17 p. [7 references]</p>
<p>This guideline meets NGC's 2013 (revised) inclusion criteria.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Guideline Availability
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Available from the <a href="http://www.med.umich.edu/1info/FHP/practiceguides/copd/copd.pdf" title="University of Michigan Health System (UMHS) Web site">University of Michigan Health System (UMHS) Web site</a>.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Availability of Companion Documents
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The supplemental methodological appendix is available from the <a href="http://www.med.umich.edu/1info/FHP/practiceguides/copd/methodological.appendix.pdf" title="University of Michigan Health System (UMHS) Web site">University of Michigan Health System (UMHS) Web site</a>.</p>
<p>A self-study continuing medical education (CME) activity for this guideline is available from <a href="http://ocpd.med.umich.edu/cme/self-study/Chronic%20Obstructive%20Pulmonary%20Disease" title="UMHS Web site">UMHS Web site</a>.</p>
<p>Performance measures are provided in the <a href="http://www.med.umich.edu/1info/FHP/practiceguides/copd/copd.pdf" title="UMHS Web site">original guideline document</a>.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Patient Resources
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Patient education materials are available on the <a href="http://www.med.umich.edu/1info/FHP/practiceguides/copd.html" title="University of Michigan Health System (UMHS) Web site">University of Michigan Health System (UMHS) Web site</a>.</p>
<p class="Disclaimer">Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
NGC Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This NGC summary was completed by ECRI Institute on October 13, 2010. This summary was updated by ECRI Institute on March 21, 2018. The information was verified by the guideline developer on April 10, 2018.</p>
<p>This NEATS assessment was completed by ECRI Institute on March 27, 2018. The information was verified by the guideline developer on April 10, 2018.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Copyright Statement
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This NGC summary is based on the original guideline, which is copyrighted by the University of Michigan Health System (UMHS).</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Disclaimer
</h2>
<div class='field field_text'>
<h3>
NGC Disclaimer
</h3>
<div class='FieldValue'>
<p>The National Guideline Clearinghouseâ„¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href="/help-and-about/summaries/inclusion-criteria">NGC Inclusion Criteria</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p>
</div>

</div>

</div>
</body></html>